Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 Versus Placebo as Part of a Treatment Regimen Including Peginterferon α-2a (Pegasys®) and Ribavirin (Copegus®) or Peginterferon α-2b (PegIntron®) and Ribavirin (Rebetol®) in Treatment-naïve, Genotype 1, Hepatitis C-infected Subjects
Brief Summary: The purpose of this study is to investigate the effectiveness and safety of TMC435 compared with placebo in participants who are infected with genotype 1 hepatitis C virus who have never received treatment before. Participants will also receive peginterferon alfa-2a or peginterferon alfa-2b and ribavirin as part of their treatment.


Options:
A: Arm Label: Treatment A: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment B: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment C: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment D: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment E: PSI-7977 + Daclatasvir + Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir, Drug: Ribavirin | Arm Label: Treatment F: PSI-7977 + Daclatasvir+ Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir, Drug: Ribavirin | Arm Label: Treatment G: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment H: PSI-7977 + BMS-790052 + Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir, Drug: Ribavirin | Arm Label: Treatment I: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment J: PSI-7977 + Daclatasvir + Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir, Drug: Ribavirin | Intervention Type: DRUG; Name: PSI-7977; Assigned to Arm(s): Treatment A: PSI-7977 + Daclatasvir, Treatment B: PSI-7977 + Daclatasvir, Treatment C: PSI-7977 + Daclatasvir, Treatment D: PSI-7977 + Daclatasvir, Treatment E: PSI-7977 + Daclatasvir + Ribavirin, Treatment F: PSI-7977 + Daclatasvir+ Ribavirin, Treatment G: PSI-7977 + Daclatasvir, Treatment H: PSI-7977 + BMS-790052 + Ribavirin, Treatment I: PSI-7977 + Daclatasvir, Treatment J: PSI-7977 + Daclatasvir + Ribavirin | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Treatment A: PSI-7977 + Daclatasvir, Treatment B: PSI-7977 + Daclatasvir, Treatment C: PSI-7977 + Daclatasvir, Treatment D: PSI-7977 + Daclatasvir, Treatment E: PSI-7977 + Daclatasvir + Ribavirin, Treatment F: PSI-7977 + Daclatasvir+ Ribavirin, Treatment G: PSI-7977 + Daclatasvir, Treatment H: PSI-7977 + BMS-790052 + Ribavirin, Treatment I: PSI-7977 + Daclatasvir, Treatment J: PSI-7977 + Daclatasvir + Ribavirin | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Treatment E: PSI-7977 + Daclatasvir + Ribavirin, Treatment F: PSI-7977 + Daclatasvir+ Ribavirin, Treatment H: PSI-7977 + BMS-790052 + Ribavirin, Treatment J: PSI-7977 + Daclatasvir + Ribavirin
B: Arm Label: Placebo 12 Weeks (GT2/3); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match SOF, Drug: Placebo to match RBV | Arm Label: SOF 12 Weeks (GT2/3); Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV | Arm Label: SOF 24 Weeks (GT3); Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV | Intervention Type: DRUG; Name: SOF; Assigned to Arm(s): SOF 12 Weeks (GT2/3), SOF 24 Weeks (GT3) | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): SOF 12 Weeks (GT2/3), SOF 24 Weeks (GT3) | Intervention Type: DRUG; Name: Placebo to match SOF; Assigned to Arm(s): Placebo 12 Weeks (GT2/3) | Intervention Type: DRUG; Name: Placebo to match RBV; Assigned to Arm(s): Placebo 12 Weeks (GT2/3)
C: Arm Label: Telaprevir 750 mg with Peg-IFN-alfa-2a/RBV tablet; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2a, Drug: Ribavirin (RBV) tablet | Arm Label: Telaprevir 750 mg with Peg-IFN-alfa-2b/RBV capsule; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2b, Drug: Ribavirin (RBV) capsule | Arm Label: Telaprevir 1125 mg with Peg-IFN-alfa-2a/RBV tablet; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2a, Drug: Ribavirin (RBV) tablet | Arm Label: Telaprevir 1125 mg with Peg-IFN-alfa-2b/RBV capsule; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2b, Drug: Ribavirin (RBV) capsule | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Telaprevir 1125 mg with Peg-IFN-alfa-2a/RBV tablet, Telaprevir 1125 mg with Peg-IFN-alfa-2b/RBV capsule, Telaprevir 750 mg with Peg-IFN-alfa-2a/RBV tablet, Telaprevir 750 mg with Peg-IFN-alfa-2b/RBV capsule | Intervention Type: DRUG; Name: Peg-IFN-alfa-2a; Assigned to Arm(s): Telaprevir 1125 mg with Peg-IFN-alfa-2a/RBV tablet, Telaprevir 750 mg with Peg-IFN-alfa-2a/RBV tablet | Intervention Type: DRUG; Name: Peg-IFN-alfa-2b; Assigned to Arm(s): Telaprevir 1125 mg with Peg-IFN-alfa-2b/RBV capsule, Telaprevir 750 mg with Peg-IFN-alfa-2b/RBV capsule | Intervention Type: DRUG; Name: Ribavirin (RBV) tablet; Assigned to Arm(s): Telaprevir 1125 mg with Peg-IFN-alfa-2a/RBV tablet, Telaprevir 750 mg with Peg-IFN-alfa-2a/RBV tablet | Intervention Type: DRUG; Name: Ribavirin (RBV) capsule; Assigned to Arm(s): Telaprevir 1125 mg with Peg-IFN-alfa-2b/RBV capsule, Telaprevir 750 mg with Peg-IFN-alfa-2b/RBV capsule
D: Arm Label: TMC435; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b), Drug: Ribavirin (RBV) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b), Drug: Ribavirin (RBV) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): TMC435 | Intervention Type: DRUG; Name: Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b); Assigned to Arm(s): Placebo, TMC435 | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): Placebo, TMC435

Answer: D